Century Therapeutics (IPSC) Retained Earnings (2020 - 2026)

Century Therapeutics (IPSC) has reported Retained Earnings for 7 consecutive years, with -$813.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings fell 15.27% year-over-year to -$813.6 million; the TTM figure through Mar 2026 stood at -$813.6 million (down 15.27% YoY), while the FY2025 annual figure was -$791.9 million, down 1.22% from the prior year.
• Retained Earnings eased to -$813.6 million in Q1 2026 per IPSC's latest filing, from -$791.9 million in the prior quarter.
• Across five years, Retained Earnings topped out at $758000.0 in Q3 2024 and bottomed at -$813.6 million in Q1 2026.
• Historically, Retained Earnings has averaged -$474.8 million across 5 years, with a median of -$550.4 million in 2023.
• Annual changes were most pronounced in 2022 — Retained Earnings plunged 15222133.33% — and 2025, when it jumped 126.86%.
• Century Therapeutics' Retained Earnings stood at -$519.1 million in 2022, then slipped by 26.33% to -$655.8 million in 2023, then retreated by 19.3% to -$782.3 million in 2024, then declined by 1.22% to -$791.9 million in 2025, then fell by 2.73% to -$813.6 million in 2026.
• Business Quant data shows IPSC's Retained Earnings at -$813.6 million in Q1 2026, -$791.9 million in Q4 2025, and $64000.0 in Q3 2025.